Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection

Journal of Infectious Diseases

Volumn 193, Issue 1, 2006, Pages 129-135

  Sabharwal, Hemant ^a,b   Michon, Francis ^d   Nelson, Daniel ^c   Dong, Wenling ^d   Fuchs, Kathleen ^b   Manjarrez, Roberto Carreño ^f   Sarkar, Arun ^d   Uitz, Catherine ^d   Viteri Jackson, Ann ^a   Rodriguez Suarez, Romeo S ^g   Blake, Milan ^e   Zabriskie, John B ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Microbiology Immunology   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d BioVeris Corporation   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^g National Center for the Health of Infants and Adolescents   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARBOHYDRATE; CYTOSKELETON PROTEIN; M PROTEIN; OPSONIN; STREPTOCOCCUS GROUP A CARBOHYDRATE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; THROAT CULTURE;

ADOLESCENT; ANIMALS; ANTIBODIES, BACTERIAL; CARBOHYDRATES; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; MEXICO; MICE; PHARYNX; POLYSACCHARIDES, BACTERIAL; RABBITS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 29744463674     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/498618     Document Type: Article

References (20)

1. Salvadori LG, Blake MS, McCarty M, Tai JY, Zabriskie JB. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis 1995;171:593-600.
2. Lancefield RC, Todd EW. Antigenic differences between matt hemolytic streptococci and their glossy variants. J Exp Med 1928;48:769-90.
3. Hessen D, Fischetti VA. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 1988; 56:2666-72.
4. Pancholi V, Fischetti VA. Isolation and characterization of the cell-associated region of group A streptococcal M protein. J Bacteriol 1988; 170:2618-24.
5. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1011-8.
6. Fillit HM, Blake MS, McCarty M. Immunogenicity of liposome bound hyaluronate in mice. J Exp Med 1988;168:971-82.
7. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Nat Acad Sci USA 2001; 98:4107-12.
8. Zabriskie JB. Rheumatic fever: the interplay between host, genetics, and microbe. Circulation 1985; 71:1077-86.
9. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2:285-314.
10. Cunningham MW. Autoimmunity and molecular mimicry in the pathogen esis of post-streptococcal heart disease. Front Biosci 2003; 8:s533-43.
11. Schmidt WC, Moore DJ. The determination of antibody to group A streptococcal polysaccharide in human sera by agglutination. J Exp Med 1965; 121:793-806.
12. Zimmerman RA, Auernheimer AH, Taranta A. Precipitating antibody to group A streptococcal polysaccharide in humans. J Immunol 1971; 107:832-41.
13. Todome Y, Ohkuni H, Yokomuro K, et al. Enzyme-linked immunosorbent assay of antibody to group A streptococcus-specific C carbohydrate with trypsin-pronase-treated whole cells as antigen. J Clin Microbiol 1988; 26:464-70.
14. Sahu A, Pangburn MK. Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 1993; 30:679-84.
15. Almeda S, Rosenberg RD, Bing DH. The binding properties of human complement component C1q: interaction with mucopolysaccharides. J Biol Chem 1983; 258:785-91.
16. Mollnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988; 73:484-8.
17. Nilsson M, Weineisen M, Andersson T, Truedsson L, Sjobring U. Critical role for complement receptor 3 (CD11b/CD18), but not for Fc receptors, in killing Streptococcus pyogenes by neutrophils in human immune serum. Eur J Immunol 2005; 35:1472-81.
18. Shikhman AR, Cunningham MW. Immunological mimicry between N-acetyl-β-D-glucosamine and cytokeratin peptides. Evidence for a microbially driven anti-keratin antibody response. J Immunol 1994; 152:4375-87.
19. Shikhman AR, Greenspan NS, Cunningham MW. Cytokeratin peptide SFGSGFGGGY mimics N-acetyl-β-D-glucosamine in reaction with antibodies and lectins, and induces in vivo anti-carbohydrate antibody response. J Immunol 1994; 153:5593-606.
20. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9:914-20.